2-丁基-5-甲基-2H-吡唑-3-胺 | 3524-35-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-丁基-5-甲基-2H-吡唑-3-胺
• 英文名称: 1-butyl-3-methyl-1H-pyrazol-5-amine
• 英文别名: 2-butyl-5-methyl-2H-pyrazol-3-ylamine；1-butyl-5-amino-3-methyl-pyrazole；1-Butyl-3-methyl-5-aminopyrazol；2-butyl-5-methylpyrazol-3-amine
• CAS: 3524-35-4
• 化学式: C₈H₁₅N₃
• 分子量: 153.227
• InChiKey: QOULOAPGXXMZCG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933199090

反应信息

• 作为反应物：
  描述：

  2-丁基-5-甲基-2H-吡唑-3-胺 在 氢氧化钾 、 ammonium hydroxide 、 氯化亚砜 、 三氯氧磷 作用下， 以 四氢呋喃 、 乙二醇二甲醚 为溶剂， 生成 1-Butyl-4-chloro-3-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid amide
  参考文献：
  名称：

  Discovery of New Orally Active Phosphodiesterase (PDE4) Inhibitors

  摘要：

  合成了一系列4-氨基吡唑并吡啶衍生物，并对其作为磷酸二酯酶（PDE4）抑制剂进行生物评估。对3这一我们内部库中发现的结构新颖的化学先导物的化学改造主要集中在1-和3-取代基上。本文详细介绍了新型口服活性化学先导物5的发现，以及结构-活性关系数据、药理评估和亚型选择性研究的结果。

  DOI：

  10.1248/cpb.52.1098
• 作为产物：
  描述：

  3-氨基巴豆腈 、 正丁基肼盐酸盐 在 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 18.0h， 生成 2-丁基-5-甲基-2H-吡唑-3-胺
  参考文献：
  名称：

  Discovery and Characterization of 1H-Pyrazol-5-yl-2-phenylacetamides as Novel, Non-Urea-Containing GIRK1/2 Potassium Channel Activators

  摘要：

  The G protein-gated inwardly-rectifying potassium channels (GIRK, KO) are a family of inward-rectifying potassium channels, and there is significant evidence supporting the roles of GIRKs in a number of physiological processes and as potential targets for numerous indications. Previously reported urea containing molecules as GIRK1/2 preferring activators have had significant pharmacokinetic (PK) liabilities. Here we report a novel series of 1H-pyrazolo-5yl-2-phenylacetamides in an effort to improve upon the PK properties. This series of compounds display nanomolar potency as GIRK1/2 activators with improved brain distribution (rodent K-p > 0.6).

  DOI：

  10.1021/acschemneuro.7b00217

文献信息

• [EN] INHIBITORS OF FATTY ACID BINDING PROTEIN (FABP)<br/>[FR] INHIBITEURS DE LA PROTÉINE DE LIAISON AUX ACIDES GRAS (FABP)
  申请人：SCHERING CORP

  公开号：WO2010056631A1

  公开（公告）日：2010-05-20

  The present invention relates to novel heterocyclic compounds as Fatty Acid Binding Protein ("FABP") inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the present invention is shown below: (I)

  本发明涉及新型杂环化合物作为脂肪酸结合蛋白（"FABP"）抑制剂，包括该杂环化合物的药物组合物以及利用该化合物治疗或预防心血管疾病、代谢紊乱、肥胖或与肥胖相关的疾病、糖尿病、血脂异常、糖尿病并发症、糖耐量受损或空腹血糖受损的用途。本发明的一个示例化合物如下所示：（I）
• (1,3-Dialkyl-5-amino-1H-pyrazol-4-yl)arylmethanones. A series of novel central nervous system depressants
  作者：Donald E. Butler、Lawrence D. Wise、Horace A. DeWald

  DOI：10.1021/jm00377a003

  日期：1984.11

  was synthesized. Pharmacological evaluation of these compounds demonstrated central nervous system depressant activity, potential anticonvulsant properties, and a low order of acute toxicity. In addition, selected compounds showed potential antipsychotic effects. This report focuses on the synthesis and structure-activity relationships of these compounds. (5-Amino-1-ethyl-3-methyl-1H-pyrazol-4-yl)(2-chlorophenyl)

  合成了一系列新颖的（1,3-二烷基-5-氨基-1H-吡唑-4-基）芳基甲烷酮。这些化合物的药理评估表明，中枢神经系统抑制活性，潜在的抗惊厥性质和低毒性的急性毒性。另外，选定的化合物显示出潜在的抗精神病作用。本报告重点介绍这些化合物的合成与构效关系。（5-氨基-1-乙基-3-甲基-1H-吡唑-4-基）（2-氯苯基）甲酮（21）是对抗戊四唑诱发的惊厥最有效的化合物。（5-氨基-1,3-二甲基-1H-吡唑-4-基）（3-氯苯基）甲酮（4）也具有良好的抗惊厥抑郁率。（5-氨基-1,3-二甲基-1H-吡唑-4-基）（3-三氟甲基苯基）甲烷一（8），（5-氨基-1,3-二甲基-1H-吡唑-4-基）（ 3-噻吩基）甲酮（13），和（5-氨基-3-乙基-1-甲基-1H-吡唑-4-基）苯基甲酮（14）是非常有效的抑制剂。（5-氨基-1,3-二甲基-1H-吡唑-4-基）（2-噻吩基）甲酮（12）具有显着的中央
• Discovery of Novel Pyrazolo-pyridone DCN1 Inhibitors Controlling Cullin Neddylation
  作者：Ho Shin Kim、Jared T. Hammill、Daniel C. Scott、Yizhe Chen、Jaeki Min、Jonah Rector、Bhuvanesh Singh、Brenda A. Schulman、R. Kiplin Guy

  DOI：10.1021/acs.jmedchem.9b00410

  日期：2019.9.26

  Chemical control of cullin neddylation is attracting increased attention based largely on the successes of the NEDD8-activating enzyme (E1) inhibitor pevonedistat. Recently reported chemical probes enable selective and time-dependent inhibition of downstream members of the neddylation trienzymatic cascade including the co-E3, DCN1. In this work, we report the optimization of a novel class of small molecule inhibitors of the DCN1-UBE2M interaction. Rational X-ray co-structure enabled optimization afforded a 2S-fold improvement in potency relative to the initial screening hit. The potency gains are largely attributed to additional hydrophobic interactions mimicking the N-terminal acetyl group that drives binding of UBE2M to DCN1. The compounds inhibit the protein-protein interaction, block NEDD8 transfer in biochemical assays, engage DCN1 in cells, and selectively reduce the steady-state neddylation of Cul1 and Cul3 in two squamous carcinoma cell lines harboring DCN1 amplification.
• INHIBITORS OF FATTY ACID BINDING PROTEIN (FABP)
  申请人：Schering Corporation

  公开号：EP2358716A1

  公开（公告）日：2011-08-24
• US4006127A
  申请人：——

  公开号：US4006127A

  公开（公告）日：1977-02-01